Immunomodulation with antibodies: clinical application in ovarian cancer and other malignancies. Export

@article{citeulike:6011821, abstract = {This review identifies the role of antibodies in the field of therapeutic cancer vaccines. Ovarian cancer is used as a model to review advances in therapeutic vaccine development with a focus on antibodies as immunomodulators and antigen mimetics, highlighting research on B43.13 and ACA125. The interaction of biological immunomodulation and chemotherapy is discussed. Requirements of antigen processing and recent advances in the field of dendritic cell biology are critical to current understanding of potent immune response induction. Future directions including use of growth factors, adjuvants and cellular therapies to enhance effects may potentiate observed effects and provide clues for application in many cancers and beyond oncology.}, author = {Nicodemus, Christopher F. and Schultes, Birgit C. and Hamilton, Brian L.}, citeulike-article-id = {6011821}, citeulike-linkout-0 = {http://dx.doi.org/10.1586/14760584.1.1.35}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/12908511}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=12908511}, doi = {10.1586/14760584.1.1.35}, issn = {1476-0584}, journal = {Expert review of vaccines}, keywords = {antibodies, cancer, immunomodulation, ovarian, vaccines}, month = {June}, number = {1}, pages = {35--48}, posted-at = {2009-10-26 15:22:48}, priority = {2}, title = {Immunomodulation with antibodies: clinical application in ovarian cancer and other malignancies.}, url = {http://dx.doi.org/10.1586/14760584.1.1.35}, volume = {1}, year = {2002} }

TY - JOUR ID - citeulike:6011821 L3 - citeulike-article-id:6011821 N2 - This review identifies the role of antibodies in the field of therapeutic cancer vaccines. Ovarian cancer is used as a model to review advances in therapeutic vaccine development with a focus on antibodies as immunomodulators and antigen mimetics, highlighting research on B43.13 and ACA125. The interaction of biological immunomodulation and chemotherapy is discussed. Requirements of antigen processing and recent advances in the field of dendritic cell biology are critical to current understanding of potent immune response induction. Future directions including use of growth factors, adjuvants and cellular therapies to enhance effects may potentiate observed effects and provide clues for application in many cancers and beyond oncology. IS - 1 JF - Expert review of vaccines SN - 1476-0584 EP - 48 TI - Immunomodulation with antibodies: clinical application in ovarian cancer and other malignancies. VL - 1 SP - 35 KW - antibodies KW - cancer KW - immunomodulation KW - ovarian KW - vaccines AU - Nicodemus, Christopher AU - Schultes, Birgit AU - Hamilton, Brian PY - 2002/06// UR - http://dx.doi.org/10.1586/14760584.1.1.35 ER -